Baxter International

GE HealthCare Announces Changes in Strategic Leadership and Key Segments to Better Serve Patients and Customers

Retrieved on: 
月曜日, 6月 10, 2024
Other Health, Software, General Health, Radiology, Pharmaceutical, Hardware, Data Management, Medical Devices, Technology, Biotechnology, Medical Supplies, Health, IGT, Novo Nordisk, Patient, Caption, GE HealthCare, Growth, Medical device, Pulse, Movement, Bill, Investment, Medication, Baxter International, Lead, Artificial intelligence, Boston Scientific, Medical imaging

Both leaders bring to their roles decades of deep experience in healthcare innovation and experience leading global teams in businesses of scale.

Key Points: 
  • Both leaders bring to their roles decades of deep experience in healthcare innovation and experience leading global teams in businesses of scale.
  • This also highlights the depth of internal talent that GE HealthCare is building to strengthen focus on delivering for patients and customers.
  • Aligning IGT and Ultrasound positions GE HealthCare to be more agile and address future imaging needs using these real-time modalities in both inpatient and outpatient settings.
  • Phil joined GE HealthCare in 2022 to lead IGT and has delivered significant accretive revenue growth for the business during his tenure.

Baxter to Present at Goldman Sachs 45th Annual Global Healthcare Conference

Retrieved on: 
木曜日, 6月 6, 2024
Professional Services, Health, Health Technology, Finance, General Health, Banking, Baxter International, Medtech, Conference

Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024.
  • Joel Grade, Baxter’s chief financial officer, is scheduled to present at 8:40 a.m. Eastern Time.
  • The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Monday, December 9, 2024.

Rockwell Medical Promotes Tim Chole to Chief Commercial Officer

Retrieved on: 
木曜日, 5月 30, 2024
Other Manufacturing, Medical Supplies, Other Science, Research, Packaging, General Health, Logistics, Supply Chain Management, Manufacturing, Medical Devices, Small Business, Public Relations, Investor Relations, Human Resources, Other Transport, Marketing, Trucking, Communications, Transport, Professional Services, Social Media, Health, Science, Allergan, Patient, Economics, Rockwell Medical, AKI, Actavis, Dialysis, Kidney disease, University, Gambro, SVP, Baxter International, Product marketing, The Company, Therapy, Kidney, Pharmaceutical industry

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Tim Chole was promoted to Chief Commercial Officer, reporting to the Company's President and CEO, Dr. Mark Strobeck.

Key Points: 
  • Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Tim Chole was promoted to Chief Commercial Officer, reporting to the Company's President and CEO, Dr. Mark Strobeck.
  • Mr. Chole joined Rockwell Medical in December 2019 as SVP, Sales and Marketing.
  • Mr. Chole has more than 20 years' experience in commercial leadership roles for pharmaceutical and medical device companies.
  • Prior to joining Rockwell Medical, Mr. Chole served as the Director of Product Marketing and Professional Education for hearing implants at Cochlear Americas.

New Cohort Study Data Shows Baxter’s Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years

Retrieved on: 
水曜日, 5月 29, 2024
Research, Surgery, Medical Devices, Hospitals, Biotechnology, Health, Pharmaceutical, General Health, Science, Patient, Cardiovascular disease, Doctor of Philosophy, HDX, HF, HDF, Dialysis, HD, Congress, Blood, Baxter International, Kidney, MB, Mortality, MCO, ID, Inflammation, Pharmaceutical industry

The study, “Survival of expanded hemodialysis and high-flux hemodialysis patients in Colombia: a cohort study,” was presented at the 61st Congress of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress, May 23-26.

Key Points: 
  • The study, “Survival of expanded hemodialysis and high-flux hemodialysis patients in Colombia: a cohort study,” was presented at the 61st Congress of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress, May 23-26.
  • The new data is from a 48-month observational cohort study involving 1,092 dialysis patients at 11 Baxter Renal Care Services Centers in Colombia.
  • In the study, 533 patients received high-flux hemodialysis and were compared to 559 patients who received HDx therapy.
  • “It is very exciting to see the results of this four-year study, indicating approximately 25% lower mortality for chronic kidney patients with the use of Baxter’s Theranova dialyzer.

Investigation Alert Baxter International, Eagle Pharmaceuticals, BioXcel Therapeutics, and ImmunityBio: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

Retrieved on: 
水曜日, 5月 15, 2024
Baxter International, Patient, Good manufacturing practice, Food, CMOS, FDA, Therapy, Safety, SAN, Complaint, LLP, Lung cancer, Agitation, BLA, Institutional review board, Dementia, GMP, Record, Pharmaceutical industry

Johnson Fistel, LLP is investigating potential claims on behalf of Baxter International, Inc. (NYSE: BAX).

Key Points: 
  • Johnson Fistel, LLP is investigating potential claims on behalf of Baxter International, Inc. (NYSE: BAX).
  • Defendants’ failure to disclose Baxter’s true problems relating to its supply chain deceived investors about the Company’s true financial health and earnings.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Eagle Pharmaceuticals, Inc. against certain of its officers and directors.
  • Johnson Fistel, LLP is investigating potential claims on behalf of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) against certain of its officers and directors.

Baxter to Present at Jefferies 2024 Global Healthcare Conference

Retrieved on: 
木曜日, 5月 23, 2024
Professional Services, Health, Health Technology, Finance, General Health, Banking, Conference, Baxter International, Medtech

Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Jefferies 2024 Global Healthcare Conference on Wednesday, June 5, 2024.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Jefferies 2024 Global Healthcare Conference on Wednesday, June 5, 2024.
  • Joel Grade, Baxter’s chief financial officer, is scheduled to present at 9:30 a.m. Eastern Time.
  • The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Monday, December 2, 2024.

Baxter Announces Mission and Logo for Proposed Kidney Care Company Vantive

Retrieved on: 
水曜日, 5月 15, 2024
Biotechnology, General Health, Biometrics, Health, Pharmaceutical, Patient, Baxter, Baxter International, Medtech, Sale, Multimedia, Pharmaceutical industry

Baxter International Inc. (NYSE:BAX), a global medtech leader, announced today the mission and logo for its proposed kidney care and acute therapies company, to be named Vantive .

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, announced today the mission and logo for its proposed kidney care and acute therapies company, to be named Vantive .
  • View the full release here: https://www.businesswire.com/news/home/20240515943576/en/
    Baxter announced the mission and logo for its proposed kidney care and acute therapies company, to be named Vantive.
  • (Graphic: Business Wire)
    The Vantive mission, Extending Lives, Expanding Possibilities, will guide and inspire the proposed company, which will focus on vital organ therapies for acute and chronic kidney diseases and beyond.
  • Baxter announced in 2023 plans to create a new Kidney Care company from its Renal Care and Acute Therapies businesses.

Baxter Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication

Retrieved on: 
月曜日, 5月 13, 2024
Medical Supplies, Women, FDA, Baby, Maternity, Fitness & Nutrition, Biotechnology, General Health, Pharmaceutical, Consumer, Health, Patient, Oleic acid, Route of administration, Risk, Olive oil, Tubing (recreation), Parenteral nutrition, Soybean oil, Chinese, Growth, Baxter International, Malnutrition, U.S. FDA, Dietary supplement

Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, today announced U.S. FDA approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) to be used in pediatric patients, including preterm and term neonates.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, today announced U.S. FDA approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) to be used in pediatric patients, including preterm and term neonates.
  • Clinolipid is Baxter’s proprietary mixed oil lipid emulsion that is used to provide calories and essential fatty acids in parenteral (intravenous) nutrition (PN) when oral or enteral nutrition is not possible, insufficient or contraindicated.
  • Clinolipid has been available in the U.S. for adults since 2019 and is now available for use in all ages.
  • Over the last several years, clinical practice has shifted away from using 100 percent soybean oil lipid emulsions – which was the standard of care for decades – to mixed lipid emulsions.

Baxter to Present at Bank of America 2024 Health Care Conference

Retrieved on: 
火曜日, 5月 7, 2024
Professional Services, Medical Supplies, Health, Other Health, Finance, General Health, Banking, Hospital, Baxter International, Nursing care plan, Patient, Bank, Conference, Medtech, Caregiver

Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Bank of America 2024 Health Care Conference on Wednesday, May 15, 2024.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Bank of America 2024 Health Care Conference on Wednesday, May 15, 2024.
  • Joel Grade, Baxter’s chief financial officer, is scheduled to present at 3:00 p.m. Pacific Time.
  • The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Wednesday, August 14, 2024.
  • Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care.

Diality Welcomes Ravi Parthasarathy as Chief Technology Officer

Retrieved on: 
火曜日, 5月 7, 2024
Medical Devices, Health, Kidney disease, Motorola, Moda, Research, Baxter International, ICU Medical, General Motors, Patient, CSO, Inc., Quality of life, Management

Diality Inc. , a medical device company developing the Moda-flxTM Hemodialysis System, today announced that Ravi Parthasarathy has joined the company as Chief Technology Officer.

Key Points: 
  • Diality Inc. , a medical device company developing the Moda-flxTM Hemodialysis System, today announced that Ravi Parthasarathy has joined the company as Chief Technology Officer.
  • Parthasarathy comes to Diality with decades of product development team leadership experience, most recently with ICU Medical, where he served as Vice President, Device Engineering.
  • Prior to ICU Medical, he served in leadership and product development roles for Baxter Healthcare, Motorola, Siemens Medical Systems, and General Motors.
  • “We are delighted to welcome someone of Ravi’s expertise and passion to Diality,” said Osman Khawar, M.D., CEO of Diality.